Pulmocide's Series A Round

Pulmocide raised a round of funding on November 20, 2013.

Pulmocide is a biotechnology firm developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus.…

Articles about Pulmocide's Series A Round: